Company focused to development of non-invasive diagnostics for cancer and inflammatory diseases.
Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.
The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award winning ReCIVA Breath Sampler ensures reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.
The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.
Visit website: https://www.owlstonemedical.com/
People at Owlstone Medical
Owlstone Medical News
Owlstone Medical raised $58M to advance its breath biopsy technology
FierceBiotech - 07-Sep-2021
Developing painless tests to detect lung cancer, liver diseases, respiratory diseases, and gut healthRead more...
Cancer breathalyser starts clinical trial for wide range of cancers
Guardian - 03-Jan-2019
VOCs in breath captured by mask sent to lab for diagnosis - avoids invasive testsRead more...
Lung cancer breath test trialled
BBC - 14-Feb-2015
Clinically trials planned for this yearRead more...